Monthly
US$200
Billed every month
注射用硫酸艾沙康唑
Companies, stages and changes, with each record available on this page.
Last 90 days: Marketing application approved: 2 applicationsAccepted: 4 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders31View records ↓
Under-review filings15View records ↓
This year’s generic filers4View records ↓
NHSA approval numbers32View records ↓
API companies with A status9View records ↓
Chemical-drug catalogue
Loaded records: 31 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 31 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 海南灵康制药有限公司 | 海南灵康制药有限公司 | 国药准字H20266031 | 2026/09/22 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海口市制药厂有限公司 | 海口市制药厂有限公司 | 国药准字H20266028 | 2026/09/22 | 0.2g（按 C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上药东英（江苏）药业有限公司 | 博瑞制药（苏州）有限公司 | 国药准字H20265930 | 2026/09/15 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 桂林南药股份有限公司 | 苏州二叶制药有限公司 | 国药准字H20265952 | 2026/09/15 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏迪赛诺制药有限公司 | 江苏迪赛诺制药有限公司 | 国药准字H20265586 | 2026/08/04 | 0.2g(按C22H17F2N5OS计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南倍特药业有限公司 | 海南倍特药业有限公司 | 国药准字H20265593 | 2026/08/04 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南皇隆制药股份有限公司 | 海南皇隆制药股份有限公司 | 国药准字H20265106 | 2026/07/08 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖北午时医药研究院有限公司 | 湖北午时药业股份有限公司 | 国药准字H20264965 | 2026/06/23 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江华海药业股份有限公司 | 浙江华海药业股份有限公司 | 国药准字H20264498 | 2026/05/27 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川美大康华康药业有限公司 | 四川美大康华康药业有限公司 | 国药准字H20264419 | 2026/05/19 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南广升誉制药有限公司 | 重庆博腾药业有限公司 | 国药准字H20264373 | 2026/05/19 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 武汉海特生物制药股份有限公司 | 武汉海特生物制药股份有限公司 | 国药准字H20264302 | 2026/05/12 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州中美华东制药有限公司 | 杭州中美华东制药有限公司 | 国药准字H20264222 | 2026/05/07 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 河南欣泰药业有限公司 | 河南欣泰药业有限公司 | 国药准字H20264226 | 2026/05/07 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南科伦制药有限公司 | 湖南科伦制药有限公司 | 国药准字H20264032 | 2026/04/14 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南通用三洋药业有限公司 | 海南通用三洋药业有限公司 | 国药准字H20263524 | 2026/03/10 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 内蒙古白医制药股份有限公司 | 内蒙古白医制药股份有限公司 | 国药准字H20263500 | 2026/03/03 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川宏明博思药业有限公司 | 四川宏明博思药业有限公司 | 国药准字H20256404 | 2025/12/30 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都天台山制药股份有限公司 | 成都天台山制药股份有限公司 | 国药准字H20256477 | 2025/12/30 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广州一品红制药有限公司 | 广州一品红制药有限公司 | 国药准字H20255224 | 2025/08/26 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东齐都药业有限公司 | 山东齐都药业有限公司 | 国药准字H20255036 | 2025/07/29 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东力诺制药有限公司 | 山西德元堂药业有限公司 | 国药准字H20254537 | 2025/06/17 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华北制药股份有限公司 | 华北制药股份有限公司 | 国药准字H20254299 | 2025/05/27 | 0.2g(按C22H17F2N5OS计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东新华制药股份有限公司 | 山西普德药业有限公司 | 国药准字H20254347 | 2025/05/27 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆希韦医药科技有限公司 | 重庆博腾药业有限公司 | 国药准字H20254057 | 2025/04/30 | 0.2g（按 C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 齐鲁制药（海南）有限公司 | 齐鲁制药（海南）有限公司 | 国药准字H20253662 | 2025/03/18 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏奥赛康药业有限公司 | 江苏奥赛康药业有限公司 | 国药准字H20243631 | 2024/04/30 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华润双鹤药业股份有限公司 | 华润双鹤药业股份有限公司 | 国药准字H20266339 | 2026/10/20 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川制药制剂有限公司 | 四川制药制剂有限公司 | 国药准字H20265392 | 2026/07/28 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海宣泰医药科技股份有限公司 | 湖南科伦制药有限公司 | 国药准字H20256410 | 2025/12/30 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南金瑞宝医药科技有限公司 | 重庆博腾药业有限公司 | 国药准字H20256483 | 2025/12/30 | 0.2g（按C22H17F2N5OS计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 32 distinct approval numbers and 32 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 广州一品红制药有限公司 | 国药准字H20255224 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010101012 | NHSA |
| 江苏奥赛康药业有限公司 | 国药准字H20243631 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010101425 | NHSA |
| 江苏迪赛诺制药有限公司 | 国药准字H20265586 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010101495 | NHSA |
| 武汉海特生物制药股份有限公司 | 国药准字H20264302 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010101938 | NHSA |
| 成都天台山制药股份有限公司 | 国药准字H20256477 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010102066 | NHSA |
| 四川美大康华康药业有限公司 | 国药准字H20264419 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010102087 | NHSA |
| 四川制药制剂有限公司 | 国药准字H20265392 | 0.2g(按 C₂₂H₁₇F₂N₅OS 计) | Category B (乙) | XJ02ACA370B001010102297 | NHSA |
| 华北制药股份有限公司 | 国药准字H20254299 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010102690 | NHSA |
| 河南欣泰药业有限公司 | 国药准字H20264226 | 0.2g(按 C₂₂H₁₇F₂N₅OS 计) | Category B (乙) | XJ02ACA370B001010103091 | NHSA |
| 内蒙古白医制药股份有限公司 | 国药准字H20263500 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010103889 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20255036 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010104145 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H20254347 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010104187 | NHSA |
| 海南卫康制药(潜山)有限公司 | 国药准字H20256213 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010104384 | NHSA |
| 杭州中美华东制药有限公司 | 国药准字H20264222 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010104520 | NHSA |
| 浙江华海药业股份有限公司 | 国药准字H20264498 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010104647 | NHSA |
| 湖南科伦制药有限公司 | 国药准字H20264032 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010104948 | NHSA |
| 海南皇隆制药股份有限公司 | 国药准字H20265106 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010105781 | NHSA |
| 海南倍特药业有限公司 | 国药准字H20265593 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010105791 | NHSA |
| 海南灵康制药有限公司 | 国药准字H20266031 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010105793 | NHSA |
| 海南通用三洋药业有限公司 | 国药准字H20263524 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010105821 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20253662 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010105847 | NHSA |
| 福安药业集团湖北人民制药有限公司 | 国药准字H20256127 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010109554 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20264373 | 0.2g(按 C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010181251 | NHSA |
| 合肥亿帆生物制药有限公司 | 国药准字H20255440 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010182719 | NHSA |
| 山东力诺制药有限公司 | 国药准字H20254537 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010183093 | NHSA |
| Pfizer Australia Pty Ltd | 国药准字HJ20220054 | 200mg(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010183103 | NHSA |
| 上海宣泰医药科技股份有限公司 | 国药准字H20256410 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010183135 | NHSA |
| 海南金瑞宝医药科技有限公司 | 国药准字H20256483 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010184246 | NHSA |
| 湖北午时医药研究院有限公司 | 国药准字H20264965 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010184568 | NHSA |
| 重庆希韦医药科技有限公司 | 国药准字H20254057 | 0.2g(按 C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010184682 | NHSA |
| 四川宏明博思药业有限公司 | 国药准字H20256404 | 0.2g(按C22H17F2N5OS计) | Category B (乙) | XJ02ACA370B001010184827 | NHSA |
| 江苏奥赛康药业有限公司 | 国药准字H20243631 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010201425 | NHSA |
| 江苏迪赛诺制药有限公司 | 国药准字H20265586 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010201495 | NHSA |
| 武汉海特生物制药股份有限公司 | 国药准字H20264302 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010201938 | NHSA |
| 成都天台山制药股份有限公司 | 国药准字H20256477 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010202066 | NHSA |
| 河南欣泰药业有限公司 | 国药准字H20264226 | 0.2g(按 C₂₂H₁₇F₂N₅OS 计) | Category B (乙) | XJ02ACA370B001010203091 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20255036 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010204145 | NHSA |
| 海南卫康制药(潜山)有限公司 | 国药准字H20256213 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010204384 | NHSA |
| 海南倍特药业有限公司 | 国药准字H20265593 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010205791 | NHSA |
| 海南通用三洋药业有限公司 | 国药准字H20263524 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010205821 | NHSA |
| 福安药业集团湖北人民制药有限公司 | 国药准字H20256127 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010209554 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20255036 | 0.2g(按C₂₂H₁₇F₂N₅OS计) | Category B (乙) | XJ02ACA370B001010304145 | NHSA |
| 海口市制药厂有限公司 | 国药准字H20266028 | 0.2g(按 C₂₂H₁₇F₂N₅OS 计) | Category B (乙) | XJ02ACA370B001010105758 | NHSA |
| 海口市制药厂有限公司 | 国药准字H20266028 | 0.2g(按 C₂₂H₁₇F₂N₅OS 计) | Category B (乙) | XJ02ACA370B001010205758 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 15 filings and 14 distinct first applicants.
Supplement 3 · Generic 11 · Import re-registration 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 齐鲁制药（海南）有限公司;齐鲁制药(海南)有限公司 | CYHB2601641 | Supplement | 2026/08/26 | Not stated by source | CDE |
| 山东鲁抗医药股份有限公司;成都通德药业有限公司 | CYHS2601214 | Generic | 2026/06/01 | Not stated by source | CDE |
| 山东益康药业股份有限公司;江苏海岸药业有限公司 | CYHS2602216 | Generic | 2026/09/07 | Not stated by source | CDE |
| 天津红日药业股份有限公司;江苏海岸药业有限公司 | CYHS2503292 | Generic | 2025/09/05 | Not stated by source | CDE |
| 江苏德礼生物股份有限公司;江苏金丝利药业股份有限公司 | CYHS2600027 | Generic | 2026/01/05 | Not stated by source | CDE |
| 海南广升誉制药有限公司;重庆博腾药业有限公司 | CYHB2601779 | Supplement | 2026/09/21 | Not stated by source | CDE |
| Pfizer Australia Pty Ltd;Simtra US LLC;Pfizer Investment CO. Ltd. | JYHZ2600217 | Import re-registration | 2026/09/08 | Not stated by source | CDE |
| 乳源东阳光药业有限公司 | CYHS2600412 | Generic | 2026/02/09 | Not stated by source | CDE |
| Pfizer Australia Pty Ltd;Simtra US LLC;Patheon Italia SPA | JYHB2500549 | Supplement | 2025/10/21 | Not stated by source | CDE |
| 北京海步医药科技有限公司;成都通德药业有限公司 | CYHS2503169 | Generic | 2025/08/29 | Not stated by source | CDE |
| 湖北美林药业有限公司 | CYHS2503091 | Generic | 2025/08/23 | Not stated by source | CDE |
| 石药集团欧意药业有限公司 | CYHS2502915 | Generic | 2025/08/11 | Not stated by source | CDE |
| 湖南华纳大药厂股份有限公司 | CYHS2502811 | Generic | 2025/08/04 | Not stated by source | CDE |
| 牡丹江友搏药业有限责任公司 | CYHS2502101 | Generic | 2025/06/12 | Not stated by source | CDE |
| 湖北凯安晨医药科技有限公司;山西普德药业有限公司 | CYHS2403824 | Generic | 2024/11/08 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 4 filings and 4 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 山东鲁抗医药股份有限公司;成都通德药业有限公司 | CYHS2601214 | Generic | 2026/06/01 | Not stated by source | CDE |
| 山东益康药业股份有限公司;江苏海岸药业有限公司 | CYHS2602216 | Generic | 2026/09/07 | Not stated by source | CDE |
| 江苏德礼生物股份有限公司;江苏金丝利药业股份有限公司 | CYHS2600027 | Generic | 2026/01/05 | Not stated by source | CDE |
| 乳源东阳光药业有限公司 | CYHS2600412 | Generic | 2026/02/09 | Not stated by source | CDE |
API registrations
Non-component matches: 9 companies with A status and 6 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 硫酸艾沙康唑 | 浙江赛默制药有限公司 | Y20260000693 | I | Exact ingredient | 2026/08/24 | CDE |
| 硫酸艾沙康唑 | 山东益康药业股份有限公司 | Y20250001110 | I | Exact ingredient | 2025/11/18 | CDE |
| 硫酸艾沙康唑 | 湖南华纳大药厂手性药物有限公司 | Y20250000478 | I | Exact ingredient | 2025/07/09 | CDE |
| 硫酸艾沙康唑 | 哈药集团三精明水药业有限公司 | Y20250000303 | I | Exact ingredient | 2025/04/22 | CDE |
| 硫酸艾沙康唑 | 福安药业集团重庆博圣制药有限公司 | Y20240001226 | A | Exact ingredient | 2026/08/26 | CDE |
| 硫酸艾沙康唑 | 湖南赛隆药业有限公司 | Y20240001110 | I | Exact ingredient | 2024/11/06 | CDE |
| 硫酸艾沙康唑 | 石家庄龙泽制药股份有限公司 | Y20240001116 | A | Exact ingredient | 2026/05/07 | CDE |
| 硫酸艾沙康唑 | 广东先强药业有限公司 | Y20240000732 | I | Exact ingredient | 2024/07/24 | CDE |
| 硫酸艾沙康唑 | 上药康丽（常州）药业有限公司 | Y20230001128 | A | Exact ingredient | 2025/12/29 | CDE |
| 硫酸艾沙康唑 | 上海迪赛诺化学制药有限公司 | Y20230001386 | A | Exact ingredient | 2026/04/11 | CDE |
| 硫酸艾沙康唑 | 江西国药有限责任公司 | Y20230001378 | A | Exact ingredient | 2026/06/02 | CDE |
| 硫酸艾沙康唑 | 四川伊诺达博医药科技有限公司 | Y20230000865 | A | Exact ingredient | 2026/06/16 | CDE |
| 硫酸艾沙康唑 | 四川科伦药业股份有限公司 | Y20230000518 | A | Exact ingredient | 2026/10/14 | CDE |
| 硫酸艾沙康唑 | 博瑞制药（苏州）有限公司 | Y20230000572 | A | Exact ingredient | 2025/03/14 | CDE |
| 硫酸艾沙康唑 | 南京海润医药有限公司 | Y20210001068 | A | Exact ingredient | 2026/02/09 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/03Marketing application approved
南京易亨制药有限公司
CYHS2500956 · 国药准字H20266460
Fact date: 2026/11/03 · Publication date: 2026/11/05 · Site observation date: 2026/11/06
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 36 ↗ -
2026/10/20Marketing application approved
华润双鹤药业股份有限公司
CYHS2404575 · 国药准字H20266339
Fact date: 2026/10/20 · Publication date: 2026/10/22 · Site observation date: 2026/11/03
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 15 ↗ -
2026/09/21Accepted
海南广升誉制药有限公司;重庆博腾药业有限公司
CYHB2601779
Fact date: 2026/09/21 · Site observation date: 2026/10/22
View source ↗ -
2026/09/08Accepted
Pfizer Australia Pty Ltd;Simtra US LLC;Pfizer Investment CO. Ltd.
JYHZ2600217
Fact date: 2026/09/08 · Site observation date: 2026/10/22
View source ↗ -
2026/09/07Accepted
山东益康药业股份有限公司;江苏海岸药业有限公司
CYHS2602216
Fact date: 2026/09/07 · Site observation date: 2026/10/21
View source ↗ -
2026/08/26Accepted
齐鲁制药（海南）有限公司;齐鲁制药(海南)有限公司
CYHB2601641
Fact date: 2026/08/26 · Site observation date: 2026/10/21
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to this drug
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy